Cracking The Code: Understanding Analyst Reviews For Sage Therapeutics

破译密码：了解sage therapeutics的分析师评论

Benzinga · 2024/11/20 06:00

Providing a diverse range of perspectives from bullish to bearish, 10 analysts have published ratings on Sage Therapeutics (NASDAQ:SAGE) in the last three months.

在过去三个月中，有10位分析师公布了对Sage Therapeutics（纳斯达克股票代码：SAGE）的评级，提供了从看涨到看跌的不同视角。

The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.

下表汇总了他们最近的评级，阐明了过去30天内情绪的变化，并将其与前几个月进行了比较。

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $12.2, a high estimate of $26.00, and a low estimate of $4.00. Highlighting a 33.7% decrease, the current average has fallen from the previous average price target of $18.40.

分析师评估的12个月目标股价揭示了进一步的见解，平均目标价为12.2美元，最高估计为26.00美元，低估值为4.00美元。当前的平均价格已从之前的平均目标股价18.40美元有所下降，这凸显了33.7％的跌幅。

Diving into Analyst Ratings: An In-Depth Exploration

深入分析师评级：深度探索

The standing of Sage Therapeutics...

通过对分析...

登录免费看全文

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。更多信息

Cracking The Code: Understanding Analyst Reviews For Sage Therapeutics

Cracking The Code: Understanding Analyst Reviews For Sage Therapeutics

风险及免责提示

声明